News
10-22-2018, 12:00 AM
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., (Merck: known as MSD outside the US and Canada) today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA® (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
More... (https://www.news-medical.net/news/20181022/LYNPARZA-Phase-III-SOLO-1-results-show-improved-outcome-for-patients-with-advanced-BRCA-mutated-ovarian-cancer.aspx)
More... (https://www.news-medical.net/news/20181022/LYNPARZA-Phase-III-SOLO-1-results-show-improved-outcome-for-patients-with-advanced-BRCA-mutated-ovarian-cancer.aspx)